Keyphrases
Interleukin-6
100%
Chemotherapy
100%
Sigma Phase
100%
Non-Hodgkin Lymphoma
100%
Leukemia-lymphoma
100%
Chronic Lymphocytic Leukemia
100%
Microgram
75%
Treatment Cycle
25%
Leukemia Patients
25%
Proliferation Rate
25%
Labeling Index
25%
High Sensitivity
12%
Tumor Cells
12%
Progressive Disease
12%
Partial Remission
12%
Last Days
12%
Recombinant Human
12%
Stimulatory Effect
12%
Second-line Treatment
12%
CD20
12%
Inducer
12%
Human interleukin-6
12%
Regulatory Effect
12%
Bromodeoxyuridine
12%
Cytostatic
12%
CHOP Chemotherapy
12%
Immunophenotypic Profile
12%
Growth Regulators
12%
CD20 Expression
12%
Anti-CD20 Antibody Treatment
12%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 6
100%
Chemotherapy
100%
Nonhodgkin Lymphoma
100%
Chronic Lymphatic Leukemia
100%
Disease
14%
Neoplasm
14%
Remission
14%
Cytostatic Agent
14%
Broxuridine
14%
CD20 Antibody
14%
Lymphocytic Lymphoma
14%
Neuroscience
Interleukin 6
100%
Non-Hodgkin Lymphoma
100%
In Vivo
66%
CD20
66%
In Vitro
33%
Bromodeoxyuridine
33%
CHOP
33%
CD20 Antibody
33%
Nursing and Health Professions
Interleukin 6
100%
Nonhodgkin Lymphoma
100%
Chronic Lymphatic Leukemia
100%
Labeling Index
28%
Disease
14%
Neoplasm
14%
Remission
14%
Cytostatic Agent
14%
Percentage of Cells in S Phase
14%
Patient with Leukemia
14%
Lymphocytic Lymphoma
14%
CD20 Antibody
14%
Broxuridine
14%
Biochemistry, Genetics and Molecular Biology
Interleukin 6
100%
S Phase
100%
CD20
100%
Bromodeoxyuridine
33%
Percentage of Cells in S Phase
33%